Skip to Main Content

WASHINGTON — Congress’ efforts to get more information on the business practices of pharmacy benefit managers are running into an unlikely roadblock: Republicans’ dislike of Federal Trade Commission Chair Lina Khan and her approach to antitrust enforcement.

The Senate Commerce Committee held a hearing Thursday on a bipartisan bill that aims to get the drug middlemen to tell the FTC how much money they make through pharmacy fees and “spread pricing,” a practice of charging insurers more for drugs than the PBMs pay pharmacies, and pocketing the difference.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment